Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience

Table 3

Summary of the ten most frequently reported treatment related toxicities.

Adverse effect	Total (all grades) n (%)	Grade 3 or 4 n (%)
Alopecia	69 (95.8)	0
Fatigue	71 (98.6)	2 (2.6)
Nausea	49 (68.1)	0
Vomiting	15 (20.8)	1 (1.3)
Diarrhoea	53 (73.6)	2 (2.6)
Constipation	41 (56.9)	1 (1.3)
Mucositis	50 (69.4)	1 (1.3)
Palmar-planter syndrome	23 (31.9)	0
Peripheral neuropathy	40 (55.6)	0
Infection	40 (55.6)	4 (5.2)